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Abstract
Background—Hypospadias is a frequent birth defect with three phenotypic subtypes. With data 
from the National Birth Defects Prevention Study, a large, multi-state, population-based, case-
control study, we compared risk factors for second and third degree hypospadias.
Methods—A wide variety of data on maternal and pregnancy-related risk factors for isolated 
second and third degree hypospadias was collected via computer-assisted telephone interviews to 
identify potential etiological differences between the two phenotypes. Logistic regression was 
used to calculate odds ratios including a random effect by study center.
Results—In total, 1547 second degree cases, 389 third degree cases, and 5183 male controls 
were included in our study. Third degree cases were more likely to have a non-Hispanic black or 
Asian/Pacific Islander mother, be delivered preterm, have a low birth weight, be small for 
gestational age, and be conceived with fertility treatments than second degree cases and controls. 
Associations with both second and third degree hypospadias were observed for maternal age, 
family history, parity, plurality, and hypertension during pregnancy. Risk estimates were generally 
higher for third degree hypospadias except for family history.
Conclusions—Most risk factors were associated with both or neither phenotype. Therefore, it is 
likely that the underlying mechanism is at least partly similar for both phenotypes. However, some 
associations were different between 2nd and 3rd degree hypospadias, and went in opposite 
directions for second and third degree hypospadias for Asian/Pacific Islander mothers. Effect 
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estimates for subtypes of hypospadias may be over- or underestimated in studies without 
stratification by phenotype.
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Introduction
Hypospadias is one of the most commonly occurring birth defects, affecting four to six per 
1000 male births (Paulozzi, 1999; Paulozzi and others, 1997; Porter and others, 2005). In 
hypospadias, the urethral opening is displaced to a certain degree, varying from placement 
just off the tip of the penis to a perineal meatus. Three phenotypic subgroups are identified 
and classified as first degree hypospadias when the urethral opening is located at the glans or 
corona, second degree hypospadias when it is located on the shaft of the penis, and third 
degree hypospadias when the urethra ends in the penoscrotal region, scrotum, or perineum. 
Patients often undergo surgery in the first two years of life, but may still encounter medical, 
social, and sexual problems later in life (Mieusset and Soulie, 2005; Schonbucher and 
others, 2008). Also, the complication rates of surgery are relatively high, especially with the 
more severe forms of hypospadias (Eassa and others, 2011; Nuininga and others, 2005).
So far, several risk factors for hypospadias have been proposed, including assisted 
reproductive technology (Brouwers and others, 2007; Brouwers and others, 2010; 
Carmichael and others, 2007), maternal hypertension during pregnancy (Akre and others, 
2008; Caton and others, 2008), thyroid disease (Browne and others, 2009), high maternal 
age at delivery (Carmichael and others, 2012; Carmichael and others, 2003; Porter and 
others, 2005), and maternal obesity (Akre and others, 2008; Brouwers and others, 2010). 
Associations with low birth weight, preterm birth, and primiparity are well established 
(Porter and others, 2005; van der Zanden and others, 2012). Familial clustering points 
towards a genetic contribution to the etiology of hypospadias (Carmichael and others, 2012; 
Harris, 1990; Schnack and others, 2008).
In a study assessing phenotypic differences, Brouwers et al. (2010) found evidence for 
etiological heterogeneity between the different hypospadias phenotypes. Others found 
additional associations (van Rooij and others, 2013), but the few studies investigating risk 
factors for different hypospadias phenotypes were too small to draw firm conclusions. In the 
present study, data from the National Birth Defects Prevention Study (NBDPS), a large 
case-control study, were used to investigate etiological heterogeneity of second and third 
degree hypospadias.
Methods
Study design
Data for this study were collected through the NBDPS, a multi-state, population-based, case-
control study funded by the Centers for Disease Control and Prevention (CDC) since 1997. 
Ten states (Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, New York, 
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North Carolina, Texas and Utah) collected data from mothers of infants with one of 37 birth 
defects and mothers of live born control infants without major birth defects. A wide range of 
potential risk factors were assessed using a standardized maternal interview. The NBDPS 
obtained approval from the institutional review boards for all study sites, and all participants 
provided informed consent. Participation rates were 65% among the mothers of both eligible 
cases and controls. Details on study methods have been described elsewhere (Yoon and 
others, 2001).
Case classification
Case infants were identified from population-based surveillance systems and reviewed by 
clinical geneticists to determine study eligibility. Second-degree hypospadias was defined as 
an infant with the urethral meatus on the shaft (penile), which also included subglanular and 
subcoronal hypospadias. Third-degree hypospadias was defined as an infant with the 
urethral meatus in the scrotum or perineum (scrotal, perineal). Cases were excluded if they 
had a karyotype other than XY, a known or suspected chromosome abnormality, a 
diagnosed single gene condition, or a hormonal profile or anatomical feature consistent with 
disorders of sex development. Controls were live born males without major birth defects 
randomly selected from birth certificates or hospital records in the 10 participating states. 
Cases and controls had estimated dates of delivery (EDD) between October 1, 1997 and 
December 31, 2009. Analyses were performed only on cases with isolated hypospadias 
(90.1% of all cases), since these may be more homogeneous etiologically.
Exposure assessment
Mothers were interviewed between 6 weeks and 24 months after the estimated date of 
delivery using a computer-assisted telephone interview. On average, case mothers were 
interviewed 13 months after EDD and control mothers 9 months after EDD. The interviews 
included detailed questions about exposures between three months before conception and 
date of delivery (Rasmussen and others, 2003). Several potential risk factors were selected 
from literature and assessed in the maternal interview: maternal age at EDD, self-defined 
race or ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, Asian/Pacific Islander, 
or other), education (0-12 years or >12 years of schooling), pre-pregnancy body mass index 
(BMI), and parity (number of previous pregnancies over 20 weeks resulting in a live birth or 
stillbirth). Family history was defined as hypospadias reported in the infant's first degree 
relatives or one of the mother's previous pregnancies. Fertility problems were assessed via a 
gateway question and several follow-up questions to get more details on possible fertility 
treatments. Subjects with exposure to in vitro fertilization (IVF) or intracytoplasmic sperm 
injection (ICSI) and clomiphene citrate were only included in the IVF/ICSI category. 
Maternal smoking, alcohol consumption, cannabis use, and intake of folic acid-containing 
supplements were examined between one month before conception and the third month of 
pregnancy. References categories for smoking and cannabis use consisted of mothers who 
did not report exposure between three months preconception and the end of pregnancy and 
for alcohol and folic acid-containing supplements until the end of the third month of 
pregnancy. We analyzed any use of alcohol (yes/no) and binge drinking (defined as 4 or 
more drinks consumed on one occasion).
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Three aspects of maternal health were considered: diabetes mellitus (pre-existing type I or II 
or gestational diabetes during index pregnancy), chronic and gestational hypertensive 
disorders, and thyroid disorders. Hypertensive disorders were classified into three groups: 
untreated hypertension, hypertension with early antihypertensive medication (exposure 
before the fifth month of pregnancy), or hypertension with late exposure to medication (first 
exposure between the fifth month of pregnancy and delivery). Mothers who used 
antihypertensive medication but did not report a hypertensive disorder (n=46) and mothers 
who reported a diagnosis of hypertension after the index pregnancy (n=20) were excluded 
from these analyses. Thyroid disorders were identified through reports of thyroid disease or 
exposure to thyroid medication and reviewed by a clinician blinded to case-control status.
Besides the maternal interview, information about birth weight and gestational age was 
collected from birth records. Criteria for being small for gestational age (SGA) were adopted 
from a United States growth reference (Alexander and others, 1996).
Statistical Analysis
Using unconditional logistic regression, crude odds ratios (cORs) with 95% confidence 
intervals (CIs) were calculated for the above-mentioned variables, comparing second and 
third degree cases with controls. All potential risk factors were then included in a single 
logistic model for each phenotype to estimate adjusted odds ratios. A random effect 
parameter was included to adjust for study center differences. Analyses compared cases to 
controls stratified by phenotype, using a complete case analysis. Plurality and fertility 
treatment were combined in one variable to avoid multicollinearity in the model. No ORs 
were calculated for risk factors with less than three exposed cases. For those factors that 
showed associations when cases were compared to controls, we estimated odds ratios for 3rd 
degree versus 2nd degree cases using the same logistic regression method. The results from 
the binomial models were validated through a multinomial model containing both subtypes 
and controls. Data analyses were performed using SPSS software version 20.0.
Results
The mothers of 2148 cases with second or third degree hypospadias and 5183 male controls 
were interviewed. Excluding 212 cases (123 second and 89 third degree) with multiple 
major anomalies left 1547 second degree and 389 third degree hypospadias cases for 
analysis.
Many descriptive characteristics differed among the three groups (table 1). Mean birth 
weight, gestational age, and SGA were statistically significantly different among all three 
groups (unpaired t-test, p<0.001), with the highest proportion of low or very low birth 
weight, preterm delivery, and SGA infants among third degree cases. Time to interview, 
study center, and year of EDD varied between both phenotypes and controls, as well.
Many risk factors were associated with one or both of the hypospadias subtypes in the crude 
analyses (table 2) and were included in table 3. After adjustment for confounding, the 
adjusted odds ratios (aORs) for 5 of the 15 potential risk factors were statistically 
significantly different between second and third degree hypospadias (table 3). Family 
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history of hypospadias, increasing maternal age, and primiparity were associated with both 
phenotypes. The OR for family history was higher for second than third degree hypospadias, 
although the OR for 2nd vs 3rd degree hypospadias was not statistically significant. The 
associations for maternal age and primiparity were stronger for third than second degree 
hypospadias. Decreased odds ratios were observed for second degree hypospadias for all 
racial/ethnic categories except for non-Hispanic black mothers when compared to non-
Hispanic white mothers, whereas for third degree hypospadias, elevated ORs were observed 
for non-Hispanic black and Asian/Pacific Islander mothers. Early exposure to 
antihypertensive medication was not associated with hypospadias, but exposure to 
medication later in pregnancy and untreated hypertension were associated with both 
phenotypes. These associations were stronger for third than second degree hypospadias. The 
association with thyroxin exposure was of borderline statistical significance in second 
degree hypospadias only. The associations for plurality and fertility treatments remained 
elevated when combined into a 6-level variable in the multivariable analysis. Compared to 
singleton infants conceived without assistance, increased aORs were observed for multiples 
conceived without fertility treatment for both second and third degree hypospadias. IVF/
ICSI was associated with both hypospadias phenotypes, whereas treatment with clomiphene 
citrate prior to conception was only associated with third degree hypospadias, regardless of 
plurality. Results from a multinomial model with both subtypes and controls did not differ 
substantially from the results obtained through the binomial models described above.
Discussion
Most risk factors evaluated were either associated with both second and third degree 
hypospadias or with neither phenotype, indicating that the underlying mechanism is partly 
similar for second and third degree hypospadias. Effect estimates were generally larger for 
third degree hypospadias than for second degree hypospadias, except for a family history of 
hypospadias which seemed to occur more often among second degree hypospadias.
The odds ratios for a family history of hypospadias were by far the strongest effect estimates 
observed in our study, with odds ratios of 25.9 (95% CI 13.1-51.3) for second degree 
hypospadias and 16.4 (95% CI 6.2-43.5) for third degree hypospadias. Most other studies, 
that also included first degree hypospadias cases, similarly showed lower risks for family 
history in third degree cases when compared to less severe subtypes (Brouwers and others, 
2010; Fredell and others, 2002; van Rooij and others, 2013), but one U.S. study did not 
(Bauer and others, 1979).
Associations between non-Hispanic white race/ethnicity and isolated hypospadias have been 
reported by several researchers (Carmichael and others, 2003; Porter and others, 2005; van 
der Zanden and others, 2012). For third degree hypospadias, however, the risk for non-
Hispanic white mothers was similar to that for Hispanic mothers and those with other race/
ethnicities, whereas elevated odds ratios were observed for non-Hispanic black and Asian/
Pacific Islander mothers. To our knowledge, the latter associations have not been observed 
before, but suggest that several race/ethnicities have different risks for certain phenotypes of 
hypospadias.
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A link between hypospadias and placental insufficiency was first published by Stoll et al. 
(1990), showing an association between hypospadias and low placental weight. Others 
found that hypospadias was more likely to occur in the smallest of monozygotic twins 
(Fredell and others, 1998) and that SGA newborns with hypospadias had a high rate of early 
onset intrauterine growth retardation due to placental insufficiency (Yinon and others, 
2010). Placental human chorionic gonadotropin (hCG) stimulates fetal testicular 
steroidogenesis before the fetus' own production is started, and placental insufficiency may 
result in a failure to transfer hCG to the fetus in early pregnancy (Brouwers and others, 
2007; Fredell and others, 1998). Therefore, placental insufficiency could result in both 
hypospadias and early onset intrauterine growth retardation. Our findings that boys with 
hypospadias were more likely to have a low birth weight or to be SGA support this. Since 
these associations seemed to be stronger for third degree than second degree cases, the role 
of placental insufficiency may be more prominent in the etiology of the third degree 
hypospadias phenotype.
Maternal hypertension is also associated with placental insufficiency and was found to be a 
risk factor for hypospadias in several studies (Akre and others, 2008; Brouwers and others, 
2010; Caton and others, 2008; van der Zanden and others, 2012; van Rooij and others, 
2013). An earlier NBDPS study that did not include a stratification by phenotype found that 
late exposure to antihypertensive medication was related to hypospadias and suggested that 
these cases could represent mothers with hypertension caused by severe placental 
insufficiency (Caton and others, 2008). In our analysis, which included approximately 3000 
additional controls and over 1000 additional hypospadias cases, both phenotypes were 
associated with late use of antihypertensive medication and with untreated hypertension. 
The fact that treatment started late in pregnancy might indicate that these mothers received 
treatment for gestational hypertension or (pre)eclampsia, which have been linked to 
placental insufficiency (Mayhew and others, 2004). The aOR for late treatment was higher 
for third than for second degree hypospadias, which is a new finding, supporting a more 
prominent role for placental insufficiency in the most severe phenotype.
Our findings that primiparity and multiple gestations were associated with hypospadias in 
both phenotypes, with the highest odds ratios observed for third degree hypospadias, 
confirms earlier findings (van Rooij and others, 2013). We also found some evidence for 
associations between fertility treatments and hypospadias. The largest odds ratio was seen 
for multiples with third degree hypospadias born after use of clomiphene citrate. These 
results confirm the findings by Meijer et al (2006), but differ from earlier NBDPS findings 
based on a smaller amount of data (Reefhuis and others, 2011). It was not possible to 
evaluate whether these findings were due to the treatment itself or to the underlying 
subfertility, since women were not asked about time-to-pregnancy or a possible subfertility 
diagnosis.
Because consistent case finding and classification is difficult for first degree hypospadias, 
this phenotype is not included in the NBDPS. Patients with a subglanular and subcoronal 
meatus were classified as second degree hypospadias, whereas some other studies classify 
these phenotypes as first degree hypospadias, which limits comparability. Although the risk 
factors for first and second degree hypospadias were similar in a previous study (van Rooij 
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and others, 2013), the results may not be generalizable to all phenotypes. In addition, rates 
of hypospadias varied considerably between study sites, indicating possible differences in 
case finding. We tried to adjust for this by including a random effect for study center in our 
multivariable model. Sub-analyses excluding centers with the lowest hypospadias 
prevalence rates showed no appreciable change in effect estimates. There is a possibility of 
some remaining ascertainment bias by race or fertility treatment, but we expect this to be 
minimal, and at least partially addressed by the random effect. Mothers were provided with 
pregnancy calendars before the interview to improve recall of timing of exposures, but due 
to the self-reported nature of our exposure data, recall bias cannot be ruled out. Due to the 
relatively large number of exposures studied, we cannot exclude the possibility that some of 
our findings are due to chance.
The large, population-based, multistate design of the NBDPS is one of the key strengths of 
this study. Strict case ascertainment and classification protocols ensured consistent 
classification of subtypes. The large amount of exposure data allowed us to study rare 
exposures and to adjust for many possible confounders in one multivariable model, while 
keeping sufficient statistical power. Information on timing of exposure was available, which 
created the opportunity to study exposures in early pregnancy. However, we could not assess 
the effects of exposure on the last stages of urethral closure which take place in the fourth 
month of pregnancy, as most of the data were collected by trimester after the third month of 
pregnancy.
Conclusions
The fact that most risk factors identified were associated with both phenotypes indicates that 
the embryological process is at least partly similar. Many effect estimates, however, were 
larger for third degree hypospadias than for second degree hypospadias, while our findings 
regarding race/ethnicity and fertility treatment also showed some differences between the 
two phenotypes. Since mild hypospadias is more common than severe forms, studies 
without stratification by phenotype may over- or underestimate the effects of exposures or 
the role of genetics in the more severe subtypes. Identifying etiological differences between 
hypospadias phenotypes could bring us closer to understanding the disease mechanisms and 
developing preventive strategies.
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Table 1
Descriptive characteristics of isolated hypospadias cases and male controls, National 
Birth Defects Prevention Study, 1997- 2009
Characteristic Male controls (n=5183) 2nd degree hypospadias (n=1547) 3rd degree hypospadias (n=389)
Birth weight
 Mean (in grams) 3403 3161 2391
  Very low (<1500g) 43 (0.8%) 73 (4.8%) 85 (22.4%)
  Low (1500-2499g) 248 (4.9%) 192 (12.6%) 104 (27.4%)
  Normal (2500-3999g) 4184 (82.0%) 1099 (72.4%) 177 (46.6%)
  Macrosomic (≥4000g) 628 (12.3%) 154 (10.1%) 14 (3.7%)
Gestational age
 Mean (in weeks) 38.6 38.0 35.9
  Very preterm (<32 weeks) 77 (1.5%) 71 (4.6%) 62 (16.0%)
  Preterm (32-36 weeks) 414 (8.0%) 221 (14.3%) 111 (28.7%)
  Term (37-45 weeks) 4692 (90.5%) 1255 (81.1%) 214 (55.3%)
Small for gestational age
  Yes 347 (7.0%) 211 (14.8%) 134 (41.5%)
  No 4610 (93.0%) 1213 (85.2%) 189 (58.5%)
Time from due date to interview
 Mean (in months) 9.1 14.0 12.7
center
  Arkansas 638 (12.3%) 210 (13.6%) 48 (12.3%)
  California 591 (11.4%) 53 (3.4%) 38 (9.8%)
  Georgia 544 (10.5%) 198 (12.8%) 43 (11.1%)
  Iowa 574 (11.1%) 128 (8.3%) 24 (6.2%)
  Massachusetts 619 (11.9%) 316 (20.4%) 86 (22.1%)
  New Jersey 260 (5.0%) 238 (15.4%) 48 (12.3%)
  New York 449 (8.7%) 87 (5.6%) 33 (8.5%)
  North Carolina 429 (8.3%) 144 (9.3%) 43 (11.1%)
  Texas 652 (12.6%) 17 (1.1%) 14 (3.6%)
  Utah 427 (8.2%) 156 (10.1%) 12 (3.1%)
Year of estimated date of delivery
  1997-2000 1302 (25.1%) 362 (23.4%) 103 (26.5%)
  2001-2003 1248 (24.1%) 330 (21.3%) 84 (21.6%)
  2004-2006 1346 (26.0%) 403 (26.1%) 109 (28.1%)
  2007-2009 1287 (24.8%) 452 (29.2%) 92 (23.7%)
Chordee
  Yes a 749 (48.4%) 262 (67.4%)
  No a 798 (51.6%) 127 (32.6%)
a
Data on presence of chordee in controls was not available
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Table 3
Adjusted Odds Ratios for Associations between Selected Exposures and the Risk of 
Hypospadias Stratified by Subtype, National Birth Defects Prevention Study, 1997-2009a
Variable
aOR (95% CI) for 2nd degree 
vs controls
aOR (95% CI) for 3rd degree 
vs controls
aOR (95% CI) for 3rd 
degree vs 2nd degreeb
Maternal age (per year) 1.03 (1.02-1.05) 1.07 (1.04-1.09) 1.03 (1.0-1.05)
Maternal race/ethnicity
 Non-Hispanic white 1 (ref) 1 (ref) 1 (ref)
 Non-Hispanic black 0.9 (0.8-1.2) 1.7 (1.2-2.4) 1.5 (1.0-2.2)
 Hispanic 0.3 (0.2-0.3) 0.7 (0.5-1.1) 2.3 (1.5-3.7)
 Asian/Pacific Islander 0.5 (0.3-0.8) 2.3 (1.4-3.7) 4.3 (2.3-7.7)
 Other 0.6 (0.4-0.8) 1.2 (0.7-2.2) 2.0 (1.0-3.8)
Maternal education >12 years 1.2 (1.0-1.4) 1.0 (0.7-1.4) 0.9 (0.6-1.2)
Pre-pregnancy BMI ≥30 kg/m2 1.0 (0.8-1.2) 1.1 (0.8-1.5)
Family history of hypospadiasc 25.9 (13.1-51.3) 16.4 (6.2-43.5) 0.6 (0.3-1.2)
Parity
 0 1.7 (1.5-1.9) 2.8 (2.2-3.7) 1.6 (1.2-2.1)
 ≥1 1 (ref) 1 (ref) 1 (ref)
Use of oral contraceptives after conceptiond 1.0 (0.7-1.5) 1.2 (0.6-2.3)
Maternal alcohol usee 1.1 (0.9-1.2) 1.0 (0.8-1.3)
Maternal smokingf 0.9 (0.7-1.1) 0.9 (0.7-1.3)
Maternal cannabis usef 0.7 (0.5-1.1) 0.9 (0.5-1.8)
Folic acid supplement usee 1.2 (1.0-1.5) 1.1 (0.7-1.6)
Gestational diabetes mellitus 1.2 (0.9-1.7) 0.7 (0.4-1.3)
Maternal hypertension
 Untreated hypertension 1.5 (1.2-1.8) 2.2 (1.6-3.0) 1.3 (1.0-1.9)
 Early treatment 1.2 (0.8-2.2) 1.5 (0.6-3.5) 1.4 (0.6-3.6)
 Late treatment 2.1 (1.0-4.5) 9.0 (4.3-19.1) 3.9 (1.7-9.0)
Maternal exposure to thyroxine 1.5 (1.0-2.2) 1.2 (0.6-2.7) 0.9 (0.4-1.9)
Plurality and fertility treatment
 Singleton without treatment 1 (ref) 1 (ref) 1 (ref)
 Singleton with IVF/ICSI 1.8 (0.9-3.7) 2.4 (0.9-6.2) 1.1 (0.4-3.0)
 Singleton with clomiphene citrate only 1.2 (0.8-1.8) 2.5 (1.4-4.5) 2.0 (1.1-3.7)
 Multiples without treatment 1.5 (1.0-2.3) 3.1 (1.8-5.5) 1.9 (1.0-3.4)
 Multiples with IVF/ICSI 1.9 (1.0-3.4) 5.2 (2.5-11.0) 2.2 (1.1-4.7)
 Multiples with clomiphene citrate only 1.0 (0.3-3.1) 7.5 (2.6-22.1) 5.6 (1.7-17.9)
aAnalyses were restricted to cases and controls with valid answers for all variables (1293 second degree cases, 324 third degree cases and 4300 
controls). A full model approach was used to adjust for potential confounding.
bOnly included if there was an association observed for 2nd or 3rd degree hypospadias when compared to controls
c
Family history of hypospadias in the father, a sibling or one of the mother's previous pregnancies
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d
Exposure measured any time in the first three months post-conception
e
Exposure and reference category measured between one month preconception and three months post-conception
Exposures were measured between one month preconception and three months post-conception. Reference category is no exposure between three 
months preconception and the end of pregnancy
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